Brief Introduction

HitGen is a biotech company focused on lead generation and optimization of innovative drug discovery research process. HitGen has its headquarters based in Chengdu, China. Its core technology is centered around the synthesis and screening of a rapidly expanding and proprietary DNA-encoded compound libraries of novel small and macrocyclic molecules for lead generation.

Company Overview

Full name HitGen Inc.
Abbreviations HitGen
Code 688222
Founded 22ndFeb., 2012
Listing 16thApr. 2020
Domicile Chengdu
Website https://www.hitgen.com/
Email investors@hitgen.com/info@hitgen.com
STAR Theme Biomedicine
CSRCSector Scientific research and technical service
Has weighted voting rights structure? No

Financials

Highlights

  2018 2017 2016
Earnings Per Share N/A N/A N/A
R&D expenditure as a % of operating revenue 40.92% 86.84% 97.72%
Operating Revenue 151.20 53.22 16.43
Net Income 44.96 -23.08 -22.97

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 151.20 53.22 16.43
Operating Costs 26.21 17.77 12.45
Operating Income 48.86 -29.12 -33.56
Pretax Income 48.92 -30.04 -26.64
Income Tax 3.96 -6.96 -3.67
Net Income 44.96 -23.08 -22.97

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Assets
Current Assets-Total 355.95 79.34 82.41
Non-current Assets-Total 156.13 73.98 65.51
Total Assets 512.08 153.32 147.92
Liabilities
Current Liabilities-Total 101.51 46.16 26.56
Non-current Liabilities-Total 20.90 11.64 3.39
Total Liabilities 122.41 57.80 29.94
Stockholder's Equity
Share Capital 453.59 203.43 202.76
Retained Profits -63.92 -107.90 -84.78
Total Owners' Equity 389.67 95.53 117.98

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 50.70 -1.81 -9.24
Net Cash Flows-Investing -129.41 -41.86 -6.00
Net Cash Flows-Financing 251.06 9.00 55.82

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
JIN LI 8,187.69 22.74%
Lhasa Huabo Health Development Co., Ltd 5,915.33 16.43%
成都聚智科创生物科技合伙企业(有限合伙) 3,865.12 10.74%
拉萨经济技术开发区东方佳钰投资合伙企业(有限合伙) 3,766.77 10.46%
CentralSKY Investment(Limited Partnership) 2,405.99 6.68%
成都腾澜生物技术合伙企业(有限合伙) 2,197.39 6.10%
JumboKindness Limited 1,992.56 5.54%
重庆渤溢新天股权投资基金合伙企业(有限合伙) 1,800.00 5.00%
嘉兴丹青投资合伙企业(有限合伙) 1,696.74 4.71%
杭州鼎晖新趋势股权投资合伙企业(有限合伙) 1,456.74 4.05%
 

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.